|Synta Pharmaceuticals Corp.|
45 Hartwell Avenue
United States - Map
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product pipeline includes Ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trials for the treatment of second-line advanced adenocarcinoma non-small cell lung cancer (NSCLC) with adenocarcinoma histology; in Phase IIb/III clinical trials for the treatment of adenocarcinoma NSCLC; in Phase II clinical trials for NSCLC patients whose tumors have a genetic profile characterized by rearrangement of the ALK gene and patients with newly diagnosed HER2+ and triple-negative metastatic breast cancer; in Phase II clinical trials for the treatment of breast cancer, lung cancer, acute myeloid leukemia (AML), and rectal cancer; and in Phase I/II clinical trials for treating mesothelioma and multiple myeloma, as well as has completed Phase II clinical trials for treating NSCLC. The companys product pipeline also comprises additional Hsp90 inhibitors, which are in preclinical development stage for cancer; Elesclomol, a mitochondria-targeting agent that is in Phase I/II clinical trials for ovarian cancer and Phase I clinical trials for AML; and STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer. Its product pipeline for inflammatory diseases includes CRACM ion channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
|Synta Pharmaceuticals Corp.’s ISS Governance QuickScore as of Nov 1, 2013 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Safi R. Bahcall Ph.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Dr. Lan Bo Chen Ph.D.,
|Mr. Keith S. Ehrlich CPA,
Chief Financial Officer, Principal Accounting Officer and VP of Admin. & Fin.
|Ms. Wendy E. Rieder Esq.,
VP of Intellectual Property & Legal Affairs, Gen. Counsel and Sec.
|Dr. Vojo Vukovic M.D., Ph.D.,
Chief Medical Officer and Sr. VP of Clinical Research & Regulatory Affairs
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|